• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    uniQure N.V. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    9/26/25 9:24:17 PM ET
    $QURE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $QURE alert in real time by email
    false 0001590560 00-0000000 0001590560 2025-09-25 2025-09-25 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

     

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): September 25, 2025

     

    uniQure N.V.

    (Exact Name of Registrant as Specified in Charter)

     

    The Netherlands   001-36294   N/A
    (State or Other
    Jurisdiction of Incorporation)
      (Commission
    File Number)
      (IRS Employer
    Identification No.)

     

    Paasheuvelweg 25a,
    1105 BP
    Amsterdam, The Netherlands
      N/A
    (Address of Principal Executive Offices)   (Zip Code)

     

    Registrant’s telephone number, including area code: +31-20-240-6000

     

    (Former Name or Former Address, if Changed Since Last Report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

     

      ¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

      ¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

      ¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

      ¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class:   Trading Symbol(s)   Name of each exchange on which registered:

    Ordinary Shares, par value €0.05 per share

      QURE   The Nasdaq Global Select Market

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

     

     

     

     

     

     

    Item  1.01.Entry Into a Material Definitive Agreement.

     

    On September 25, 2025, uniQure N.V. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Leerink Partners LLC, as representative of the several underwriters named therein (the “Underwriters”), relating to an underwritten public offering (the “Offering”) of 5,789,473 of the Company’s ordinary shares (the “Firm Shares”), at a price to the public of $47.50 per ordinary share, and, in lieu of ordinary shares to certain investors, pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to 526,316 of its ordinary shares (the “Pre-Funded Warrant Shares”) at the public offering price per share less the $0.0001 per share exercise price of each Pre-Funded Warrant. Under the terms of the Underwriting Agreement, the Company also granted the Underwriters an option, exercisable for 30 days from the date of the Underwriting Agreement (the “Option”), to purchase up to an additional 947,368 of the Company’s ordinary shares (the “Optional Shares” and together with the Firm Shares, the “Shares”) at the public offering price less the underwriting discounts and commissions. On September 26, 2025, the Underwriters exercised the Option in full.

     

    The Company estimates that the net proceeds from the Offering will be approximately $323.75 million after deducting underwriting discounts and commissions and estimated offering expenses.

     

    The Pre-Funded Warrants are exercisable at any time after the date of issuance. A holder of Pre-Funded Warrants may not exercise the warrant if the holder, together with its affiliates, would beneficially own more than 4.99% or 9.99% of the number of ordinary shares outstanding immediately after giving effect to such exercise. A holder of Pre-Funded Warrants may increase or decrease this percentage not in excess of 19.99% by providing at least 61 days’ prior notice to the Company.

     

    The Shares and Pre-Funded Warrants will be issued pursuant to a prospectus supplement dated September 25, 2025, and an accompanying base prospectus that form a part of the registration statement on Form S-3ASR that the Company filed with the Securities and Exchange Commission on January 7, 2025 (File No. 333-284168), which was automatically effective upon its filing. The closing of the Offering is expected to take place on or about September 29, 2025, subject to the satisfaction of customary closing conditions.

     

    The Underwriting Agreement contains customary representations, warranties, covenants and agreements by the Company, customary conditions to closing, indemnification obligations of the Company and the Underwriters, including for liabilities under the Securities Act, other obligations of the parties and termination provisions.

     

    Copies of the Underwriting Agreement and the form of Pre-Funded Warrant are attached hereto as Exhibit 1.1 and Exhibit 4.1, respectively, and are incorporated herein by reference. The foregoing description of the terms of the Underwriting Agreement and the Pre-Funded Warrants is qualified in its entirety by reference to such exhibits.

     

    The legal opinion of Rutgers & Posch N.V. as to the legality of the Shares and Pre-Funded Warrant Shares is being filed as Exhibit 5.1 to this Current Report on Form 8-K. A copy of the opinion of Morgan, Lewis & Bockius LLP relating to the legality of the issuance and sale of the Pre-Funded Warrants is filed as Exhibit 5.2 to this Current Report on Form 8-K.

     

    Item 8.01Other Events

     

    On September 25, 2025, the Company issued a press release entitled “uniQure Announces Pricing of Upsized $300 Million Public Offering.” The full text of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

     

     

     

     

    Item 9.01Financial Statements and Exhibits.

     

    (d)           Exhibits.

     

    Exhibit No.   Description
    1.1   Underwriting Agreement, dated as of September 25, 2025, by and between the Company and Leerink Partners LLC, as representative for the several underwriters named therein.
         
    4.1   Form of Pre-Funded Warrant
         
    5.1   Opinion of Rutgers & Posch N.V.
         
    5.2   Opinion of Morgan, Lewis & Bockius LLP
         
    23.1   Consent of Rutgers & Posch N.V. (included in Exhibit 5.1)
         
    23.2   Consent of Morgan, Lewis & Bockius LLP (included in Exhibit 5.2)
         
    99.1   Press Release of uniQure N.V. dated September 25, 2025.
         
    104   Cover Page Interactive Data File (embedded with the Inline XBRL document).

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

     

      UNIQURE N.V.
       
         
    Date: September 26, 2025 By: /s/ Jeannette Potts
        JEANNETTE POTTS
        Chief Legal and Compliance Officer

     

     

     

    Get the next $QURE alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $QURE

    DatePrice TargetRatingAnalyst
    8/14/2025$30.00Neutral → Outperform
    Mizuho
    4/1/2025$38.00Buy
    Chardan Capital Markets
    12/10/2024Outperform → Strong Buy
    Raymond James
    10/10/2024$20.00Outperform
    Raymond James
    2/29/2024$8.00Buy → Neutral
    Goldman
    12/19/2023$52.00 → $10.00Buy → Neutral
    Mizuho
    3/17/2022$40.00Neutral → Buy
    UBS
    12/17/2021$75.00 → $58.00Strong Buy → Outperform
    Raymond James
    More analyst ratings

    $QURE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    uniQure Announces Closing of Upsized Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares

    LEXINGTON, Mass. and AMSTERDAM, Sept. 29, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the closing of its previously announced underwritten public offering of 6,736,841 ordinary shares at a public offering price of $47.50 per share, which includes 947,368 ordinary shares issued pursuant to the exercise in full by the underwriters of their option to purchase additional ordinary shares in the offering; and, in lieu of ordinary shares to certain investors, pre-funded warrants to purchase 526,316 of its ordinary shares at the public offering price per share less th

    9/29/25 4:05:00 PM ET
    $QURE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    uniQure Announces Pricing of Upsized $300 Million Public Offering

    LEXINGTON, Mass. and AMSTERDAM, Sept. 25, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the pricing of its previously announced underwritten public offering of 5,789,473 ordinary shares at a public offering price of $47.50 per share, and, in lieu of ordinary shares to certain investors, pre-funded warrants to purchase 526,316 of its ordinary shares at the public offering price per share less the $0.0001 per share exercise price of each pre-funded warrant. The aggregate gross proceeds to uniQure from the offering, before deducting the underwriting discounts and c

    9/25/25 11:38:53 PM ET
    $QURE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Healthcare Innovation Accelerates as Four Converging Forces Drive Early Intervention Focus

    USA News Group News Commentary Issued on behalf of Avant Technologies Inc. VANCOUVER, BC, Sept. 25, 2025 /PRNewswire/ -- America's aging demographics are creating unprecedented demand for precision healthcare solutions, with population projections showing nearly one in four Americans will be over 65 by 2060[1]. Gene therapy approvals continue accelerating as the FDA recently approved breakthrough treatments targeting rare diseases[2], while AI-powered diagnostic platforms are transforming how clinicians detect conditions before symptoms appear[3]. These market-wide trends are positioning early-stage companies across diagnostics, gene therapy, and personalized medicine for significant growth

    9/25/25 9:15:00 AM ET
    $EDIT
    $HUM
    $QURE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Medical Specialities
    Biotechnology: Pharmaceutical Preparations

    $QURE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO, Managing Director Kapusta Matthew C exercised 226,316 units of Ordinary Shares at a strike of $6.52 and sold $9,382,473 worth of Ordinary Shares (226,316 units at $41.46) (SEC Form 4)

    4 - uniQure N.V. (0001590560) (Issuer)

    9/26/25 7:43:03 PM ET
    $QURE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Klemt Christian exercised 18,000 units of Ordinary Shares at a strike of $6.65 and sold $945,120 worth of Ordinary Shares (18,000 units at $52.51) (SEC Form 4)

    4 - uniQure N.V. (0001590560) (Issuer)

    9/26/25 7:37:52 PM ET
    $QURE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Abi-Saab Walid sold $20,407 worth of Ordinary Shares (1,466 units at $13.92), decreasing direct ownership by 0.97% to 150,437 units (SEC Form 4)

    4 - uniQure N.V. (0001590560) (Issuer)

    7/1/25 4:49:12 PM ET
    $QURE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $QURE
    SEC Filings

    View All

    uniQure N.V. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - uniQure N.V. (0001590560) (Filer)

    9/26/25 9:24:17 PM ET
    $QURE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by uniQure N.V.

    424B5 - uniQure N.V. (0001590560) (Filer)

    9/26/25 7:02:44 PM ET
    $QURE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by uniQure N.V.

    144 - uniQure N.V. (0001590560) (Subject)

    9/24/25 7:59:56 PM ET
    $QURE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $QURE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    uniQure upgraded by Mizuho with a new price target

    Mizuho upgraded uniQure from Neutral to Outperform and set a new price target of $30.00

    8/14/25 8:07:02 AM ET
    $QURE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chardan Capital Markets resumed coverage on uniQure with a new price target

    Chardan Capital Markets resumed coverage of uniQure with a rating of Buy and set a new price target of $38.00

    4/1/25 8:05:22 AM ET
    $QURE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    uniQure upgraded by Raymond James

    Raymond James upgraded uniQure from Outperform to Strong Buy

    12/10/24 11:36:55 AM ET
    $QURE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $QURE
    Financials

    Live finance-specific insights

    View All

    uniQure Announces Positive Topline Results from Pivotal Phase I/II Study of AMT-130 in Patients with Huntington's Disease

    ~ Pivotal study met primary endpoint; high-dose AMT-130 demonstrated statistically significant 75% disease slowing at 36 months as measured by cUHDRS compared to a propensity score-matched external control ~ ~ High-dose AMT-130 also demonstrated statistically significant slowing of disease progression as measured by TFC, a key secondary endpoint, and favorable trends across additional clinical measures ~ ~ Mean cerebrospinal fluid NfL levels were below baseline at 36 months ~ ~ AMT-130 continued to be generally well-tolerated with a manageable safety profile ~ ~ uniQure plans to submit a BLA in the first quarter of 2026, with anticipated U.S. launch later that year, pending approval ~

    9/24/25 7:05:00 AM ET
    $QURE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    uniQure Announces Second Quarter 2025 Financial Results and Highlights of Recent Company Progress

    ~ Achieved alignment with the FDA on the AMT-130 statistical analysis plan and CMC requirements to support a planned BLA submission in the first quarter of 2026; ~ Company expects to present AMT-130 topline three-year data in September 2025 ~ ~ Presented case study from first participant treated with AMT-260 for refractory mesial temporal lobe epilepsy showing 92% seizure reduction with no serious adverse events through first five months of follow up ~ ~ Appointment of Kylie O'Keefe as Chief Customer and Strategy Officer ~ ~ Cash, cash equivalents and current investment securities of approximately $

    7/29/25 7:05:00 AM ET
    $QURE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    uniQure to Announce Second Quarter 2025 Financial Results

    LEXINGTON, Mass. and AMSTERDAM, July 22, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs will report second quarter 2025 financial results before market open on Tuesday, July 29, 2025. Management will then host a conference call at 8:30 a.m. ET. The event will be webcast under the Events & Presentations section of uniQure's website at https://www.uniqure.com/investors-media/events-presentations, and following the event a replay will be archived for 90 days. Interested parties participating by phone will need to register using this online form. After registering for dial-in detai

    7/22/25 7:05:00 AM ET
    $QURE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $QURE
    Leadership Updates

    Live Leadership Updates

    View All

    uniQure Announces Appointment of Kylie O'Keefe as Chief Customer and Strategy Officer

    ~ Proven biotech executive to lead commercialization of AMT-130 in Huntington's disease ~ LEXINGTON, Mass. and AMSTERDAM, June 11, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the appointment of Kylie O'Keefe as Chief Customer and Strategy Officer, effective June 6, 2025. In this role, Ms. O'Keefe will lead the development and execution of uniQure's global commercialization strategy for AMT-130, the Company's investigational gene therapy for the treatment of Huntington's disease. Her responsibilities include all commercial functions and medical affairs. Ms. O'K

    6/11/25 8:00:00 AM ET
    $QURE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair

    NORWOOD, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP), a clinical-stage company focused on oncology and obesity, today announced the appointment of Rachelle Jacques as Chair of its Board of Directors, effective May 15. She succeeds Alan Holmer, who will remain on the Board. "We thank Alan for his over ten years of dedicated service as founding Chair of the Corbus Board," said Yuval Cohen, Ph.D., Chief Executive Officer of Corbus. "Rachelle is a seasoned biopharmaceutical executive, and we have greatly benefitted from her innovative and strategic thinking as a Board member.  We look forward to following her vision and continued leadership as we

    5/19/25 8:00:00 AM ET
    $AKTX
    $CRBP
    $QURE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    uniQure Announces Leadership Addition to Support Advancement of Clinical Programs

    LEXINGTON, Mass. and AMSTERDAM, June 26, 2023 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the appointment of Walid Abi-Saab, M.D., as Chief Medical Officer, effective immediately. He will report to Matt Kapusta, Chief Executive Officer of uniQure, and will be based in the Company's Basel, Switzerland office. Dr. Abi-Saab will be responsible for leading all clinical research and development, regulatory affairs, medical affairs, and program management at uniQure. With Dr. Abi-Saab's appointment, Dr. Ricardo Dolmetsch becomes President and Chief Scientific Officer. He

    6/26/23 7:11:42 AM ET
    $QURE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $QURE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by uniQure N.V.

    SC 13G/A - uniQure N.V. (0001590560) (Subject)

    11/14/24 12:01:42 PM ET
    $QURE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by uniQure N.V.

    SC 13G/A - uniQure N.V. (0001590560) (Subject)

    11/13/24 4:05:14 PM ET
    $QURE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by uniQure N.V.

    SC 13G/A - uniQure N.V. (0001590560) (Subject)

    10/25/24 9:48:27 PM ET
    $QURE
    Biotechnology: Pharmaceutical Preparations
    Health Care